2020-now¶

• Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model.
  Masloh S, Chevrel A, Culot M, Perrocheau A, Kalia YN, Frehel S, Gaussin R, Gosselet F, Huet S, Zeisser Labouebe M, Scapozza L.
  Pharmaceutics. 2024 Jan 16;16(1):116. doi: 10.3390/pharmaceutics16010116.

• Finite sample corrections for average equivalence testing.
  Boulaguiem Y, Quartier J, Lapteva M, Kalia YN, Victoria-Feser MP, Guerrier S, Couturier DL.
  Stat Med. 2023 Dec 19. doi: 10.1002/sim.9993.

• Enhanced topical paromomycin delivery for cutaneous leishmaniasis treatment: Passive and iontophoretic approaches.
  de Sá FAP, Andrade JFM, Miranda TC, Cunha-Filho M, Gelfuso GM, Lapteva M, Kalia YN, Gratieri T.
  Int J Pharm. 2023 Dec 15;648:123617. doi: 10.1016/j.ijpharm.2023.123617. Epub 2023 Nov 16.

• Development of an ex vivo porcine skin model for the preclinical evaluation of subcutaneously injected biomacromolecules.
  Gou S, Lapteva M, Brusini R, Flegeau K, Bourdon F, Kaya G, Faivre J, Kalia YN.
  Int J Pharm. 2023 Dec 15;648:123562. doi: 10.1016/j.ijpharm.2023.123562. Epub 2023 Oct 30.

• Polymeric micelles for cutaneous delivery of the hedgehog pathway inhibitor TAK-441: Formulation development and cutaneous biodistribution in porcine and human skin.
  Darade AR, Lapteva M, Ling V, Kalia YN.
  Int J Pharm. 2023 Sep 25;644:123349. doi: 10.1016/j.ijpharm.2023.123349. Epub 2023 Aug 24.

• Injectable Hyaluronan-Based Thermoresponsive Hydrogels for Dermatological Applications.
  Gou S, Porcello A, Allémann E, Salomon D, Micheels P, Jordan O, Kalia YN.
  Pharmaceutics. 2023 Jun 11;15(6):1708. doi: 10.3390/pharmaceutics15061708.

• Influence of Molecular Structure and Physicochemical Properties of Immunosuppressive Drugs on Micelle Formulation Characteristics and Cutaneous Delivery.
  Quartier J, Lapteva M, Boulaguiem Y, Guerrier S, Kalia YN.
  Pharmaceutics. 2023 Apr 19;15(4):1278. doi: 10.3390/pharmaceutics15041278.

• Biodistribution of progesterone in the eye after topical ocular administration via drops or inserts.
  Alambiaga-Caravaca AM, González Iglesias LG, Rodilla V, Kalia YN, López-Castellano A.
  Int J Pharm. 2023 Jan 5;630:122453. doi: 10.1016/j.ijpharm.2022.122453. Epub 2022 Nov 28.

• Bolus delivery of palonosetron through skin by tip-loaded dissolving microneedles with short-duration iontophoresis: A potential strategy to rapidly relieve emesis associated with chemotherapy.
  Kang D, Ge Q, Natabou MA, Xu W, Liu X, Xu B, Bao X, Kalia YN, Chen Y.
  Int J Pharm. 2022 Nov 25;628:122294. doi: 10.1016/j.ijpharm.2022.122294. Epub 2022 Oct 15.

• Erbium:YAG fractional laser ablation improves cutaneous delivery of pentoxifylline from different topical dosage forms.
  Gou S, Del Río-Sancho S, Laubach HJ, Kalia YN.
  Int J Pharm. 2022 Nov 25;628:122259. doi: 10.1016/j.ijpharm.2022.122259. Epub 2022 Oct 2.

• Non-Invasive Iontophoretic Delivery of Cytochrome c to the Posterior Segment and Determination of Its Ocular Biodistribution.
  González Iglesias LG, Messaoudi S, Kalia YN.
  Pharmaceutics. 2022 Aug 31;14(9):1832. doi: 10.3390/pharmaceutics14091832.

• Simultaneous Delivery of Econazole, Terbinafine and Amorolfine with Improved Cutaneous Bioavailability: A Novel Micelle-Based Antifungal "Tri-Therapy".
  Gou S, Monod M, Salomon D, Kalia YN.
  Pharmaceutics. 2022 Jan 24;14(2):271. doi: 10.3390/pharmaceutics14020271.

• Effect of mRNA Delivery Modality and Formulation on Cutaneous mRNA Distribution and Downstream eGFP Expression.
  Darade AR, Lapteva M, Hoffmann T, Mandler M, Schneeberger A, Kalia YN.
  Pharmaceutics. 2022 Jan 8;14(1):151. doi: 10.3390/pharmaceutics14010151.

• Preclinical and clinical studies to evaluate cutaneous biodistribution, safety and efficacy of UV filters encapsulated in mesoporous silica SBA-15.
  Daneluti ALM, Guerra LO, Velasco MVR, do Rosário Matos J, Baby AR, Kalia YN.
  Eur J Pharm Biopharm. 2021 Dec;169:113-124. doi: 10.1016/j.ejpb.2021.10.002. Epub 2021 Oct 9. PMID: 34637918 Free article.

• Using Porcine Jejunum Ex Vivo to Study Absorption and Biotransformation of Natural Products in Plant Extracts: Pueraria lobata as a Case Study.
  Houriet J, Arnold YE, Pellissier L, Kalia YN, Wolfender JL.
  Metabolites. 2021 Aug 14;11(8):541. doi: 10.3390/metabo11080541.

• Controlled simultaneous iontophoresis of buflomedil hydrochloride and dexamethasone sodium phosphate to the mucosa for oral submucous fibrosis.
  Tyagi V, Serna-Jiménez CE, Kalia YN.
  Int J Pharm. 2021 Sep 25;607:121009. doi: 10.1016/j.ijpharm.2021.121009.

• DESI-MS imaging to visualize spatial distribution of xenobiotics and endogenous lipids in the skin.
  Quartier J, Rao W, Slade S, Métral F, Lapteva M, Kalia YN.
  Int J Pharm. 2021 Sep 25;607:120967. doi: 10.1016/j.ijpharm.2021.120967.

• Current profile controlled transdermal delivery of pramipexole from an iontophoretic patch system in vitro and in vivo.
  Singhal M, Serna C, Merino V, Kalia YN.
  Eur J Pharm Biopharm. 2021 Sep;166:175-181. doi: 10.1016/j.ejpb.2021.06.010. Epub 2021 Jun 25.

• Polymeric micelle mediated follicular delivery of spironolactone: Targeting the mineralocorticoid receptor to prevent glucocorticoid-induced activation and delayed cutaneous wound healing.
  Dahmana N, Mugnier T, Gabriel D, Favez T, Kowalczuk L, Behar-Cohen F, Gurny R, Kalia YN.
  Int J Pharm. 2021 Jul 15;604:120773. doi: 10.1016/j.ijpharm.2021.120773.

• Polymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex.
  Quartier J, Lapteva M, Boulaguiem Y, Guerrier S, Kalia YN.
  Int J Pharm. 2021 Jul 15;604:120736. doi: 10.1016/j.ijpharm.2021.120736.

• Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
  Patel P, Pol A, Kalaria D, Date AA, Kalia Y, Patravale V.
  Eur J Pharm Biopharm. 2021 Aug;165:66-74. doi: 10.1016/j.ejpb.2021.04.026.

• The influence of skin barrier impairment on the iontophoretic transport of low and high molecular weight permeants.
  Gratieri T, Zarhloule R, Dubey S, Kalia YN.
  Int J Pharm. 2021 Jun 1;602:120607. doi: 10.1016/j.ijpharm.2021.120607.

• Effect of continuous and multi-phasic current profiles on the iontophoretic transport of pramipexole, rasagiline and huperzine A: Depicting temporal variation and biodistribution in the skin.
  Singhal M, Serna C, Kalaria D, Kalia YN.
  Int J Pharm. 2021 Mar 4;599:120445. doi: 10.1016/j.ijpharm.2021.120445.

• Co-administration of zinc phthalocyanine and quercetin via hybrid nanoparticles for augmented photodynamic therapy.
  Thakur NS, Mandal N, Patel G, Kirar S, Reddy YN, Kushwah V, Jain S, Kalia YN, Bhaumik J, Banerjee UC.
  Nanomedicine. 2021 Feb 3;33:102368. doi: 10.1016/j.nano.2021.102368.

• Iontosomes: Electroresponsive Liposomes for Topical Iontophoretic Delivery of Chemotherapeutics to the Buccal Mucosa.
  Sonaje K, Tyagi V, Chen Y, Kalia YN.
  Pharmaceutics. 2021 Jan 11;13(1):88. doi: 10.3390/pharmaceutics13010088.

• Using protease inhibitors to improve protein stability in the presence of skin: A case study on the stability of insulin like growth factor 1.
  Dubey S, Perozzo R, Scapozza L, Kalia YN.
  Eur J Pharm Biopharm. 2021 Jan;158:379-381. doi: 10.1016/j.ejpb.2020.12.009.

• Specific protein-protein interactions limit the cutaneous iontophoretic transport of interferon beta-1b and a poly-Arg interferon beta-1b analogue.
  Dubey S, Perozzo R, Scapozza L, Kalia YN.
  Int J Pharm. 2020 Nov 15;589:119913. doi: 10.1016/j.ijpharm.2020.119913.

• Using Ex Vivo Porcine Jejunum to Identify Membrane Transporter Substrates: A Screening Tool for Early-Stage Drug Development.
  Arnold YE, Kalia YN.
  Biomedicines. 2020 Sep 10;8(9):340. doi: 10.3390/biomedicines8090340.

• Tissue Levels of Flurbiprofen in the Rat Plantar Heel after Short-Duration Topical Iontophoresis are Sufficient to Induce Pharmacodynamic Responses to Local Pain Stimuli.
  Cai Y, Zhou Y, Zhang P, Kalia YN, Gratieri T, Chen Y
  Pharmaceutics. 2020 Jun 30;12(7):608. doi: 10.3390/pharmaceutics12070608.

• Targeted cutaneous delivery of etanercept using Er:YAG fractional laser ablation
  Del Río-Sancho S, Lapteva M, Sonaje K, Böhler C, Ling V, Boehncke WH, Kalia YN.
  Int J Pharm. 2020 Apr 30;580:119234. doi: 10.1016/j.ijpharm.2020.119234.

• Non-invasive targeted iontophoretic delivery of cetuximab to skin.
  Lapteva M, Sallam MA, Goyon A, Guillarme D, Veuthey JL, Kalia YN.
  Expert Opin Drug Deliv. 2020 Apr;17(4):589-602. doi: 10.1080/17425247.2020.1731470.

2015-2019¶

• Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats.
  Dahmana N, Kowalczuk L, Gabriel D, Behar-Cohen F, Gurny R, Kalia YN.
  Mol Pharm. 2019 Dec 5. doi: 10.1021/acs.molpharmaceut.9b00707

• Cutaneous Biodistribution: A High-Resolution Methodology to Assess Bioequivalence in Topical Skin Delivery.
  Quartier J, Capony N, Lapteva M, Kalia YN.
  Pharmaceutics. 2019 Sep 18;11(9). pii: E484. doi: 10.3390/pharmaceutics11090484.

• Topical iontophoresis of buflomedil hydrochloride increases drug bioavailability in the mucosa: A targeted approach to treat oral submucous fibrosis.
  Tyagi V, Sancho SD, Lapteva M, Kalia YN.
  Int J Pharm. 2019 Aug 12:118610. doi: 10.1016/j.ijpharm.2019.118610. [Epub ahead of print]

• Controlled Iontophoretic Delivery in Vitro and in Vivo of ARN14140-A Multitarget Compound for Alzheimer's Disease.
  Singhal M, Merino V, Rosini M, Cavalli A, Kalia YN.
  Mol Pharm. 2019 Aug 5;16(8):3460-3468. doi: 10.1021/acs.molpharmaceut.9b00252. Epub 2019 Jul 5

• Er:YAG fractional laser ablation for cutaneous co-delivery of pentoxifylline and d-α-tocopherol succinate: A new approach for topical treatment of radiation-induced skin fibrosis.
  Gou S, Del Rio-Sancho S, Singhal M, Laubach HJ, Kalia YN.
  Eur J Pharm Sci. 2019 Jul 1;135:22-31. doi: 10.1016/j.ejps.2019.05.007. Epub 2019 May 10.

• Polymeric micelle nanocarriers for targeted epidermal delivery of the hedgehog pathway inhibitor vismodegib: formulation development and cutaneous biodistribution in human skin.
  Kandekar SG, Singhal M, Sonaje KB, Kalia YN.
  Expert Opin Drug Deliv. 2019 Apr 17. doi: 10.1080/17425247.2019.1609449. [Epub ahead of print]

• Drug Transport across Porcine Intestine Using an Ussing Chamber System: Regional Differences and the Effect of P-Glycoprotein and CYP3A4 Activity on Drug Absorption.
  Arnold YE, Thorens J, Bernard S, Kalia YN.
  Pharmaceutics. 2019 Mar 21;11(3). pii: E139. doi: 10.3390/pharmaceutics11030139.

• Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966.
  Lapteva M, Del Río-Sancho S, Wu E, Carbonell WS, Böhler C, Kalia YN.
  Sci Rep. 2019 Jan 31;9(1):1030. doi: 10.1038/s41598-018-36966-0.

• Self-assembled mPEG-hexPLA polymeric nanocarriers for the targeted cutaneous delivery of imiquimod.
  Lapteva M, Mignot M, Mondon K, Möller M, Gurny R, Kalia YN.
  Eur J Pharm Biopharm. 2019 Jan 12. pii: S0939-6411(18)31203-7. doi: 10.1016/j.ejpb.2019.01.008. [Epub ahead of print]

• Investigation of Different Iontophoretic Currents Profiles for Short-Term Applications in Cosmetics.
  Cázares-Delgadillo J, Planard-Luong L, Gregoire S, Serna-Jiménez CE, Singhal M, Kalia YN, Merino V, Merino-Sanjuán M, Nácher A, Martínez-Gómez MA, Burnier-Yalaoui V, Barbarat P.
  Pharmaceutics. 2018 Dec 7;10(4). pii: E266. doi: 10.3390/pharmaceutics10040266.

• Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases.
  Shatz W, Aaronson J, Yohe S, Kelley RF, Kalia YN.
  Expert Opin Drug Deliv. 2018 Nov 29. doi: 10.1080/17425247.2019.1553953.

• Controlled non-invasive iontophoretic delivery of triamcinolone acetonide amino acid ester prodrugs into the posterior segment of the eye.
  Santer V, Chen Y, Kalia YN.
  Eur J Pharm Biopharm. 2018 Nov;132:157-167. doi: 10.1016/j.ejpb.2018.09.020. Epub 2018 Sep 25.

• Hydrogels in three-dimensional dendritic cell (MUTZ-3) culture as a scaffold to mimic human immuno competent subcutaneous tissue.
  Groell F, Kalia YN, Jordan O, Borchard G.
  Int J Pharm. 2018 Jun 10;544(1):297-303. doi: 10.1016/j.ijpharm.2018.04.050. Epub 2018 Apr 23.

• Hyaluronic Acid After Subcutaneous Injection-An Objective Assessment.
  Santer V, Molliard SG, Micheels P, Río-Sancho SD, Quinodoz P, Kalia YN, Salomon D.
  Dermatol Surg. 2019 Jan;45(1):108-116. doi: 10.1097/DSS.0000000000001609.

• Needle-free cutaneous delivery of living human cells by Er:YAG fractional laser ablation.
  Yu J, Dubey S, Kalia YN
  Expert Opin Drug Deliv. 2018 Jun;15(6):559-566. doi: 10.1080/17425247.2018.1472570.

• Development and validation of a fast and sensitive UHPLC-ESI-MS method for the simultaneous quantification of spironolactone and its metabolites in ocular tissues
  Dahmana N, Gabriel D, Gurny R, Kalia YN
  Biomed Chromatogr. 2018 May 16:e4287. doi: 10.1002/bmc.4287.

• Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits.
  Dahmana N, Mugnier T, Gabriel D, Kaltsatos V, Bertaim T, Behar-Cohen F, Gurny R, Kalia YN.
  Mol Pharm. 2018 Mar 5;15(3):1192-1202. doi: 10.1021/acs.molpharmaceut.7b01028. Epub 2018 Feb 15.

• Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's Disease.
  Kalaria DR, Singhal M, Patravale V, Merino V, Kalia YN.
  Eur J Pharm Biopharm. 2018 Feb 22. pii: S0939-6411(17)31365-6. doi: 10.1016/j.ejpb.2018.02.031.

• Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers.
  Kandekar SG , Del Río-Sancho S , Lapteva M , Kalia YN .
  Nanoscale. 2018 Jan 18;10(3):1099-1110. doi: 10.1039/c7nr07706h.

• Short-duration ocular iontophoresis of ionizable aciclovir prodrugs: A new approach to treat herpes simplex infections in the anterior and posterior segments of the eye.
  Chen Y, Kalia YN.
  Int J Pharm. 2018 Jan 30;536(1):292-300. doi: 10.1016/j.ijpharm.2017.11.069. Epub 2017 Dec 2

• Targeted intracorneal delivery-Biodistribution of triamcinolone acetonide following topical iontophoresis of cationic amino acid ester prodrugs.
  Santer V, Del Río Sancho S, Lapteva M, Kalia YN.
  Int J Pharm. 2017 Apr 14. pii: S0378-5173(17)30320-4. doi: 10.1016/j.ijpharm.2017.04.030. [Epub ahead of print]

• Formulation challenges for 21st century topical and transdermal delivery systems.
  Singhal M, Lapteva M, Kalia YN.
  Expert Opin Drug Deliv. 2017 Mar 30:1-4. doi: 10.1080/17425247.2017.1311320. [Epub ahead of print] No abstract available.

• Cutaneous iontophoresis of μ-conotoxin CnIIIC-A potent NaV1.4 antagonist with analgesic, anaesthetic and myorelaxant properties.
  Del Río-Sancho S, Cros C, Coutaz B, Cuendet M, Kalia YN.
  Int J Pharm. 2017 Feb 25;518(1-2):59-65. doi: 10.1016/j.ijpharm.2016.12.054. Epub 2016 Dec 26.

• Transdermal therapeutic systems for memantine delivery. Comparison of passive and iontophoretic transport.
  Del Río-Sancho S, Serna-Jiménez CE, Sebastián-Morelló M, Calatayud-Pascual MA, Balaguer-Fernández C, Femenía-Font A, Kalia YN, Merino V, López-Castellano A.
  Int J Pharm. 2017 Jan 30;517(1-2):104-111. doi: 10.1016/j.ijpharm.2016.11.038. Epub 2016 Nov 16.

• Basic principles and current status of transcorneal and transscleral iontophoresis.
  Gratieri T, Santer V, Kalia YN.
  Expert Opin Drug Deliv. 2016 Dec 11:1-12. doi: 10.1080/17425247.2017.1266334. [Epub ahead of print]

• Topical delivery of diclofenac into and across equine skin from a novel liquid diclofenac epolamine formulation.
  Del Río-Sancho S, Concas D, Oreste P, Zoppetti G, Briggs PH, Kalia YN.
  J Vet Pharmacol Ther. 2016 Dec;39(6):578-583. doi: 10.1111/jvp.12307. Epub 2016 Mar 31.

• Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.
  Gabriel D, Mugnier T, Courthion H, Kranidioti K, Karagianni N, Denis MC, Lapteva M, Kalia Y, Möller M, Gurny R.
  J Control Release. 2016 Nov 28;242:16-24. doi: 10.1016/j.jconrel.2016.09.007. Epub 2016 Sep 14.

• Erratum to
  Chen Y, Alberti I, Kalia YN.
  Eur J Pharm Biopharm. 2016 May;102:19. doi: 10.1016/j.ejpb.2016.02.011. Epub 2016 Feb 26. No abstract available.

• A UHPLC-UV Method to Quantify Skin Deposition and Transdermal Permeation of Tizanidine Hydrochloride.
  del Río-Sancho S, Merino V, López-Castellano A, Kalia YN.
  J Chromatogr Sci. 2016 May-Jun;54(5):790-5. doi: 10.1093/chromsci/bmw011. Epub 2016 Feb 17.

• Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphate in vitro and in vivo.
  Cázares-Delgadillo J, Ganem-Rondero A, Merino V, Kalia YN.
  Eur J Pharm Sci. 2016 Mar 31;85:31-8. doi: 10.1016/j.ejps.2016.01.027. Epub 2016 Jan 28.

• Fractional Laser Ablation for the Cutaneous Delivery of Triamcinolone Acetonide from Cryomilled Polymeric Microparticles: Creating Intraepidermal Drug Depots.
  Singhal M, Del Río-Sancho S, Sonaje K, Kalia YN.
  Mol Pharm. 2016 Feb 1;13(2):500-11. doi: 10.1021/acs.molpharmaceut.5b00711. Epub 2016 Jan 15.

• Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability.
  Chen Y, Alberti I, Kalia YN.
  Eur J Pharm Biopharm. 2016 Feb;99:103-13. doi: 10.1016/j.ejpb.2015.12.002. Epub 2015 Dec 11. Erratum in: Eur J Pharm Biopharm. 2016 May;102:19.

• Eur J Pharm Biopharm. 2016 Feb;99:103-13. doi: 10.1016/j.ejpb.2015.12.002. Epub 2015 Dec 11. Erratum in: Eur J Pharm Biopharm. 2016 May;102:19.

• Cutaneous biodistribution of ionizable, biolabile aciclovir prodrugs after short duration topical iontophoresis: Targeted intraepidermal drug delivery.
  Chen Y, Zahui T, Alberti I, Kalia YN.
  Eur J Pharm Biopharm. 2016 Feb;99:94-102. doi: 10.1016/j.ejpb.2015.11.010. Epub 2015 Nov 22.

• Self-assembled polymeric nanocarriers for the targeted delivery of retinoic acid to the hair follicle.
  Lapteva M, Möller M, Gurny R, Kalia YN.
  Nanoscale. 2015 Nov 28;7(44):18651-62. doi: 10.1039/c5nr04770f. Epub 2015 Oct 26.

• Synthesis of 3-azabicyclo[3.2.2]nonanes and their antiprotozoal activities.
  Seebacher W, Wolkinger V, Faist J, Kaiser M, Brun R, Saf R, Bucar F, Gröblacher B, Brantner A, Merino V, Kalia Y, Scapozza L, Perozzo R, Weis R.
  Bioorg Med Chem Lett. 2015 Apr 1;25(7):1390-3. doi: 10.1016/j.bmcl.2015.02.044. Epub 2015 Feb 28.

• Transdermal patches: history, development and pharmacology.
  Pastore MN, Kalia YN, Horstmann M, Roberts MS.
  Br J Pharmacol. 2015 May;172(9):2179-209. doi: 10.1111/bph.13059. Epub 2015 Mar 18. Review.

2010-2014¶

• Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways.
  Lapteva M, Santer V, Mondon K, Patmanidis I, Chiriano G, Scapozza L, Gurny R, Möller M, Kalia YN.
  J Control Release. 2014 Dec 28;196:9-18. doi: 10.1016/j.jconrel.2014.09.021. Epub 2014 Sep 30.

• Colloidal soft nanocarrier for transdermal delivery of dopamine agonist: ex vivo and in vivo evaluation.
  Patel P, Pol A, More S, Kalaria DR, Kalia YN, Patravale VB.
  J Biomed Nanotechnol. 2014 Nov;10(11):3291-303.

• Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.
  Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN.
  Mol Pharm. 2014 Sep 2;11(9):2989-3001. doi: 10.1021/mp400639e. Epub 2014 Aug 5.

• Understanding the poor iontophoretic transport of lysozyme across the skin: when high charge and high electrophoretic mobility are not enough.
  Dubey S, Kalia YN.
  J Control Release. 2014 Jun 10;183:35-42. doi: 10.1016/j.jconrel.2014.03.027. Epub 2014 Mar 20.

• Controlled iontophoretic delivery of pramipexole: electrotransport kinetics in vitro and in vivo.
  Kalaria DR, Patel P, Merino V, Patravale VB, Kalia YN.
  Eur J Pharm Biopharm. 2014 Sep;88(1):56-63. doi: 10.1016/j.ejpb.2014.02.002. Epub 2014 Feb 11.

• Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers.
  Gratieri T, Kalia YN.
  Int J Pharm. 2014 Jan 2;460(1-2):24-7. doi: 10.1016/j.ijpharm.2013.10.053. Epub 2013 Nov 9.

• Controlled iontophoretic transport of huperzine A across skin in vitro and in vivo: effect of delivery conditions and comparison of pharmacokinetic models.
  Kalaria DR, Patel P, Merino V, Patravale VB, Kalia YN.
  Mol Pharm. 2013 Nov 4;10(11):4322-9. doi: 10.1021/mp4004173. Epub 2013 Sep 30.

• Turning theory into practice: the development of modern transdermal drug delivery systems and future trends.
  Perumal O, Murthy SN, Kalia YN.
  Skin Pharmacol Physiol. 2013;26(4-6):331-42. doi: 10.1159/000351815. Epub 2013 Jul 29. Review.

• Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle.
  Gratieri T, Pujol-Bello E, Gelfuso GM, de Souza JG, Lopez RF, Kalia YN.
  Eur J Pharm Biopharm. 2014 Feb;86(2):219-26. doi: 10.1016/j.ejpb.2013.06.009. Epub 2013 Jun 19.

• Microstructured bicontinuous phase formulations: their characterization and application in dermal and transdermal drug delivery.
  Lapteva M, Kalia YN.
  Expert Opin Drug Deliv. 2013 Aug;10(8):1043-59. doi: 10.1517/17425247.2013.783008. Epub 2013 Apr 21. Review.

• Next generation intra- and transdermal therapeutic systems: using non- and minimally-invasive technologies to increase drug delivery into and across the skin.
  Gratieri T, Alberti I, Lapteva M, Kalia YN.
  Eur J Pharm Sci. 2013 Dec 18;50(5):609-22. doi: 10.1016/j.ejps.2013.03.019. Epub 2013 Apr 6. Review.

• Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A.
  Patel PA, Patil SC, Kalaria DR, Kalia YN, Patravale VB.
  Int J Pharm. 2013 Mar 25;446(1-2):16-23. doi: 10.1016/j.ijpharm.2013.02.014. Epub 2013 Feb 11.

• Controlled intra- and transdermal protein delivery using a minimally invasive Erbium:YAG fractional laser ablation technology.
  Bachhav YG, Heinrich A, Kalia YN.
  Eur J Pharm Biopharm. 2013 Jun;84(2):355-64. doi: 10.1016/j.ejpb.2012.11.018. Epub 2012 Nov 30.

• Mathematical models to describe iontophoretic transport in vitro and in vivo and the effect of current application on the skin barrier.
  Gratieri T, Kalia YN.
  Adv Drug Deliv Rev. 2013 Feb;65(2):315-29. doi: 10.1016/j.addr.2012.04.012. Epub 2012 May 22. Review.

• Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro.
  Kalaria DR, Patel P, Patravale V, Kalia YN.
  Int J Pharm. 2012 Nov 15;438(1-2):202-8. doi: 10.1016/j.ijpharm.2012.08.037. Epub 2012 Aug 28.

• The pharmaceutical biochemistry group: where pharmaceutical chemistry meets biology and drug delivery.
  Kalia YN, Perozzo R, Scapozza L.
  Chimia (Aarau). 2012;66(5):313-9. doi: 10.2533/chimia.2012.313. Review.

• Transcutaneous vaccination via laser microporation.
  Weiss R, Hessenberger M, Kitzmüller S, Bach D, Weinberger EE, Krautgartner WD, Hauser-Kronberger C, Malissen B, Boehler C, Kalia YN, Thalhamer J, Scheiblhofer S.
  J Control Release. 2012 Sep 10;162(2):391-9. doi: 10.1016/j.jconrel.2012.06.031. Epub 2012 Jun 29.

• Development and validation of a HPAE-PAD method for the quantification of CGP69669A, a sialyl Lewis(x) mimetic, in skin permeation studies.
  Gratieri T, Wagner B, Kalaria D, Ernst B, Kalia YN.
  Biomed Chromatogr. 2012 Apr;26(4):507-11. doi: 10.1002/bmc.1695. Epub 2011 Aug 23.

• Cutaneous iontophoretic delivery of CGP69669A, a sialyl Lewis(x) mimetic, in vitro.
  Gratieri T, Wagner B, Kalaria D, Ernst B, Kalia YN.
  Exp Dermatol. 2012 Mar;21(3):226-8. doi: 10.1111/j.1600-0625.2011.01429.x.

• Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies.
  Yu J, Kalaria DR, Kalia YN.
  J Control Release. 2011 Nov 30;156(1):53-9. doi: 10.1016/j.jconrel.2011.07.024. Epub 2011 Jul 22.

• Noninvasive transdermal iontophoretic delivery of biologically active human basic fibroblast growth factor.
  Dubey S, Perozzo R, Scapozza L, Kalia YN.
  Mol Pharm. 2011 Aug 1;8(4):1322-31. doi: 10.1021/mp200125j. Epub 2011 Jul 5.

• Using controlled laser-microporation to increase transdermal delivery of prednisone.
  Yu J, Bachhav YG, Summer S, Heinrich A, Bragagna T, Böhler C, Kalia YN.
  J Control Release. 2010 Nov 20;148(1):e71-3. doi: 10.1016/j.jconrel.2010.07.032. No abstract available.

• Non-invasive iontophoretic delivery of peptides and proteins across the skin.
  Gratieri T, Kalaria D, Kalia YN.
  Expert Opin Drug Deliv. 2011 May;8(5):645-63. doi: 10.1517/17425247.2011.566265. Epub 2011 Mar 24. Review.

• Using laser microporation to improve transdermal delivery of diclofenac: Increasing bioavailability and the range of therapeutic applications.
  Bachhav YG, Heinrich A, Kalia YN.
  Eur J Pharm Biopharm. 2011 Aug;78(3):408-14. doi: 10.1016/j.ejpb.2011.03.006. Epub 2011 Mar 21.

• Electrically-assisted delivery of an anionic protein across intact skin: cathodal iontophoresis of biologically active ribonuclease T1.
  Dubey S, Kalia YN.
  J Control Release. 2011 Jun 30;152(3):356-62. doi: 10.1016/j.jconrel.2011.03.004. Epub 2011 Mar 21.

• Novel micelle formulations to increase cutaneous bioavailability of azole antifungals.
  Bachhav YG, Mondon K, Kalia YN, Gurny R, Möller M.
  J Control Release. 2011 Jul 30;153(2):126-32. doi: 10.1016/j.jconrel.2011.03.003. Epub 2011 Mar 22.

• Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance.
  Cázares-Delgadillo J, Ganem-Rondero A, Kalia YN.
  Eur J Pharm Biopharm. 2011 Jun;78(2):278-88. doi: 10.1016/j.ejpb.2011.01.006. Epub 2011 Feb 3. Review.

• Development and validation of a rapid high-performance liquid chromatography method for the quantification of exenatide.
  Bachhav YG, Kalia YN.
  Biomed Chromatogr. 2011 Jul;25(7):838-42. doi: 10.1002/bmc.1526. Epub 2010 Sep 27.

• Effect of controlled laser microporation on drug transport kinetics into and across the skin.
  Bachhav YG, Summer S, Heinrich A, Bragagna T, Böhler C, Kalia YN.
  J Control Release. 2010 Aug 17;146(1):31-6. doi: 10.1016/j.jconrel.2010.05.025. Epub 2010 May 25.

• Comparing metoclopramide electrotransport kinetics in vitro and in vivo.
  Cázares-Delgadillo J, Aziza IB, Balaguer-Fernández C, Calatayud-Pascual A, Ganem-Rondero A, Quintanar-Guerrero D, Castellano AC, Merino V, Kalia YN.
  Eur J Pharm Sci. 2010 Oct 9;41(2):353-9. doi: 10.1016/j.ejps.2010.07.006. Epub 2010 Jul 13.

• Non-invasive iontophoretic delivery of enzymatically active ribonuclease A (13.6 kDa) across intact porcine and human skins.
  Dubey S, Kalia YN.
  J Control Release. 2010 Aug 3;145(3):203-9. doi: 10.1016/j.jconrel.2010.04.020. Epub 2010 Apr 25.

• Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: effect of experimental parameters and skin type on drug stability and transport kinetics.
  Cázares-Delgadillo J, Balaguer-Fernández C, Calatayud-Pascual A, Ganem-Rondero A, Quintanar-Guerrero D, López-Castellano AC, Merino V, Kalia YN.
  Eur J Pharm Biopharm. 2010 Jun;75(2):173-8. doi: 10.1016/j.ejpb.2010.03.011. Epub 2010 Mar 21.

• Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies.
  Cázares-Delgadillo J, Ganem-Rondero A, Quintanar-Guerrero D, López-Castellano AC, Merino V, Kalia YN.
  Eur J Pharm Sci. 2010 Mar 18;39(5):387-93. doi: 10.1016/j.ejps.2010.01.008. Epub 2010 Jan 21.

• Development and validation of an analytical method for the quantification of cytochrome c in skin transport studies.
  Bachhav YG, Kalia YN.
  Biomed Chromatogr. 2010 Jul;24(7):732-6. doi: 10.1002/bmc.1356.

2005-2009¶

• Stability of triptorelin in the presence of dermis and epidermis.
  Bachhav YG, Kalia YN.
  Int J Pharm. 2009 Aug 13;378(1-2):149-51. doi: 10.1016/j.ijpharm.2009.05.053. Epub 2009 May 30.

• Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo.
  Patel SR, Zhong H, Sharma A, Kalia YN.
  Eur J Pharm Biopharm. 2009 Jun;72(2):304-9. doi: 10.1016/j.ejpb.2008.08.006. Epub 2008 Aug 19.

• In vitro evaluation of the effect of electrotreatment on skin permeability.
  Marra F, Levy JL, Santi P, Kalia YN.
  J Cosmet Dermatol. 2008 Jun;7(2):105-11. doi: 10.1111/j.1473-2165.2008.00372.x.

• In vivo methods for the assessment of topical drug bioavailability.
  Herkenne C, Alberti I, Naik A, Kalia YN, Mathy FX, Préat V, Guy RH.
  Pharm Res. 2008 Jan;25(1):87-103. Epub 2007 Nov 6. Review.

• Effect of propylene glycol on ibuprofen absorption into human skin in vivo.
  Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH.
  J Pharm Sci. 2008 Jan;97(1):185-97.

• Transdermal delivery of cytochrome C--A 12.4 kDa protein--across intact skin by constant-current iontophoresis.
  Cázares-Delgadillo J, Naik A, Ganem-Rondero A, Quintanar-Guerrero D, Kalia YN.
  Pharm Res. 2007 Jul;24(7):1360-8. Epub 2007 Apr 25.

• In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate.
  Patel SR, Zhong H, Sharma A, Kalia YN.
  Eur J Pharm Biopharm. 2007 May;66(2):296-301. Epub 2006 Nov 14.

• Dermatopharmacokinetic prediction of topical drug bioavailability in vivo.
  Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH.
  J Invest Dermatol. 2007 Apr;127(4):887-94. Epub 2006 Nov 30.

• Ibuprofen transport into and through skin from topical formulations: in vitro-in vivo comparison.
  Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH.
  J Invest Dermatol. 2007 Jan;127(1):135-42. Epub 2006 Jul 20.

• Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations.
  Escobar-Chávez JJ, López-Cervantes M, Naïk A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A.
  J Pharm Pharm Sci. 2006;9(3):339-58. Review.

• Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.
  Abla N, Naik A, Guy RH, Kalia YN.
  Pharm Res. 2006 Aug;23(8):1842-9.

• Pig ear skin ex vivo as a model for in vivo dermatopharmacokinetic studies in man.
  Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH.
  Pharm Res. 2006 Aug;23(8):1850-6.

• Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis.
  Schuetz YB, Carrupt PA, Naik A, Guy RH, Kalia YN.
  Eur J Pharm Sci. 2006 Sep;29(1):53-9. Epub 2006 Jun 3.

• Emerging strategies for the transdermal delivery of peptide and protein drugs.
  Schuetz YB, Naik A, Guy RH, Kalia YN.
  Expert Opin Drug Deliv. 2005 May;2(3):533-48. Review.

• Capillary zone electrophoresis for the estimation of transdermal iontophoretic mobility.
  Abla N, Geiser L, Mirgaldi M, Naik A, Veuthey JL, Guy RH, Kalia YN.
  J Pharm Sci. 2005 Dec;94(12):2667-75.

• Effect of charge and molecular weight on transdermal peptide delivery by iontophoresis.
  Abla N, Naik A, Guy RH, Kalia YN.
  Pharm Res. 2005 Dec;22(12):2069-78. Epub 2005 Sep 26.

• Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin.
  Abla N, Naik A, Guy RH, Kalia YN.
  J Control Release. 2005 Nov 28;108(2-3):319-30. Epub 2005 Sep 19.

• Effect of amino acid sequence on transdermal iontophoretic peptide delivery.
  Schuetz YB, Naik A, Guy RH, Kalia YN.
  Eur J Pharm Sci. 2005 Dec;26(5):429-37. Epub 2005 Sep 6.

• Transdermal iontophoretic delivery of triptorelin in vitro.
  Schuetz YB, Naik A, Guy RH, Vuaridel E, Kalia YN.
  J Pharm Sci. 2005 Oct;94(10):2175-82. Erratum in: J Pharm Sci. 2005 Nov;94(11):2581-2.

• Transdermal iontophoretic delivery of vapreotide acetate across porcine skin in vitro.
  Schuetz YB, Naik A, Guy RH, Vuaridel E, Kalia YN.
  Pharm Res. 2005 Aug;22(8):1305-12. Epub 2005 Aug 3.

• Skin permeation enhancement by sucrose esters: a pH-dependent phenomenon.
  Cázares-Delgadillo J, Naik A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A.
  Int J Pharm. 2005 Jun 13;297(1-2):204-12.

2000-2004¶

• Enhancement of topical delivery from biodegradable nanoparticles.
  Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H.
  Pharm Res. 2004 Oct;21(10):1818-25.

• Development of an in vitro model for premature neonatal skin: biophysical characterization using transepidermal water loss.
  Sekkat N, Kalia YN, Guy RH.
  J Pharm Sci. 2004 Dec;93(12):2936-40.

• Porcine ear skin as a model for the assessment of transdermal drug delivery to premature neonates.
  Sekkat N, Kalia YN, Guy RH.
  Pharm Res. 2004 Aug;21(8):1390-7.

• Skin penetration and distribution of polymeric nanoparticles.
  Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H.
  J Control Release. 2004 Sep 14;99(1):53-62.

• Visualization of skin penetration using confocal laser scanning microscopy.
  Alvarez-Román R, Naik A, Kalia YN, Fessi H, Guy RH.
  Eur J Pharm Biopharm. 2004 Sep;58(2):301-16. Review.

• Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo.
  Curdy C, Naik A, Kalia YN, Alberti I, Guy RH.
  Int J Pharm. 2004 Mar 1;271(1-2):251-6.

• Iontophoretic drug delivery.
  Kalia YN, Naik A, Garrison J, Guy RH.
  Adv Drug Deliv Rev. 2004 Mar 27;56(5):619-58. Review.

• Effects of sucrose oleate and sucrose laureate on in vivo human stratum corneum permeability.
  Ayala-Bravo HA, Quintanar-Guerrero D, Naik A, Kalia YN, Cornejo-Bravo JM, Ganem-Quintanar A.
  Pharm Res. 2003 Aug;20(8):1267-73.

• Skin permeability enhancement by low frequency sonophoresis: lipid extraction and transport pathways.
  Alvarez-Román R, Merino G, Kalia YN, Naik A, Guy RH.
  J Pharm Sci. 2003 Jun;92(6):1138-46.

• Ultrasound-enhanced transdermal transport.
  Merino G, Kalia YN, Guy RH.
  J Pharm Sci. 2003 Jun;92(6):1125-37. Review.

• Frequency and thermal effects on the enhancement of transdermal transport by sonophoresis.
  Merino G, Kalia YN, Delgado-Charro MB, Potts RO, Guy RH.
  J Control Release. 2003 Feb 14;88(1):85-94.

• Biophysical study of porcine ear skin in vitro and its comparison to human skin in vivo.
  Sekkat N, Kalia YN, Guy RH.
  J Pharm Sci. 2002 Nov;91(11):2376-81.

• Reverse iontophoretic monitoring in premature neonates: feasibility and potential.
  Sekkat N, Naik A, Kalia YN, Glikfeld P, Guy RH.
  J Control Release. 2002 May 17;81(1-2):83-9.

• In vivo assessment of skin electroporation using square wave pulses.
  Dujardin N, Staes E, Kalia Y, Clarys P, Guy R, Préat V.
  J Control Release. 2002 Feb 19;79(1-3):219-27.

• Post-iontophoresis recovery of human skin impedance in vivo.
  Curdy C, Kalia YN, Guy RH.
  Eur J Pharm Biopharm. 2002 Jan;53(1):15-21.

• Optimizing iontophoretic drug delivery: identification and distribution of the charge-carrying species.
  Marro D, Kalia YN, Delgado-Charro MB, Guy RH.
  Pharm Res. 2001 Dec;18(12):1709-13.

• Contributions of electromigration and electroosmosis to iontophoretic drug delivery.
  Marro D, Kalia YN, Delgado-Charro MB, Guy RH.
  Pharm Res. 2001 Dec;18(12):1701-8.

• Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man.
  Alberti I, Kalia YN, Naik A, Guy RH.
  Pharm Res. 2001 Oct;18(10):1472-5. No abstract available.

• Piroxicam delivery into human stratum corneum in vivo: iontophoresis versus passive diffusion.
  Curdy C, Kalia YN, Naik A, Guy RH.
  J Control Release. 2001 Sep 11;76(1-2):73-9.

• Passive skin penetration enhancement and its quantification in vitro.
  Moser K, Kriwet K, Naik A, Kalia YN, Guy RH.
  Eur J Pharm Biopharm. 2001 Sep;52(2):103-12. Review.

• Enhanced skin permeation of a lipophilic drug using supersaturated formulations.
  Moser K, Kriwet K, Kalia YN, Guy RH.
  J Control Release. 2001 Jun 15;73(2-3):245-53.

• Assessment of topical bioavailability in vivo: the importance of stratum corneum thickness.
  Kalia YN, Alberti I, Naik A, Guy RH.
  Skin Pharmacol Appl Skin Physiol. 2001;14 Suppl 1:82-6. Review.

• Iontophoretic transport across the skin.
  Guy RH, Delgado-Charro MB, Kalia YN.
  Skin Pharmacol Appl Skin Physiol. 2001;14 Suppl 1:35-40. Review.

• Supersaturation: enhancement of skin penetration and permeation of a lipophilic drug.
  Moser K, Kriwet K, Froehlich C, Kalia YN, Guy RH.
  Pharm Res. 2001 Jul;18(7):1006-11.

• Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery.
  Moser K, Kriwet K, Kalia YN, Guy RH.
  Int J Pharm. 2001 Aug 14;224(1-2):169-76.

• Non-invasive assessment of the effects of iontophoresis on human skin in-vivo.
  Curdy C, Kalia YN, Guy RH.
  J Pharm Pharmacol. 2001 Jun;53(6):769-77. Review.

• Modeling transdermal drug release.
  Kalia YN, Guy RH.
  Adv Drug Deliv Rev. 2001 Jun 11;48(2-3):159-72. Review.

• Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo.
  Alberti I, Kalia YN, Naik A, Bonny J, Guy RH.
  Int J Pharm. 2001 May 21;219(1-2):11-9.

• In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum.
  Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH.
  J Control Release. 2001 Apr 28;71(3):319-27.

• Permeation enhancement of a highly lipophilic drug using supersaturated systems.
  Moser K, Kriwet K, Froehlich C, Naik A, Kalia YN, Guy RH.
  J Pharm Sci. 2001 May;90(5):607-16.

• Factors and strategies for improving buccal absorption of peptides.
  Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P.
  Eur J Pharm Biopharm. 2001 Mar;51(2):93-109. Review.

• Recovery of human skin impedance in vivo after iontophoresis: effect of metal ions.
  Curdy C, Kalia YN, Falson-Rieg F, Guy RH.
  AAPS PharmSci. 2000;2(3):E23.

• Normalization of stratum corneum barrier function and transepidermal water loss in vivo.
  Kalia YN, Alberti I, Sekkat N, Curdy C, Naik A, Guy RH.
  Pharm Res. 2000 Sep;17(9):1148-50. No abstract available.

• Transdermal drug delivery: overcoming the skin's barrier function.
  Naik A, Kalia YN, Guy RH.
  Pharm Sci Technolo Today. 2000 Sep 1;3(9):318-326.

• Transepidermal water loss in 24 and 25 weeks gestational age infants.
  Nonato LB, Lund CH, Kalia YN, Guy RH.
  Acta Paediatr. 2000 Jun;89(6):747-8. No abstract available.

• Iontophoresis: electrorepulsion and electroosmosis.
  Guy RH, Kalia YN, Delgado-Charro MB, Merino V, López A, Marro D.
  J Control Release. 2000 Feb 14;64(1-3):129-32. Review.

1995-1999¶

• Electrorepulsion versus electroosmosis: effect of pH on the iontophoretic flux of 5-fluorouracil.
  Merino V, López A, Kalia YN, Guy RH.
  Pharm Res. 1999 May;16(5):758-61.

• Ion mobility across human stratum corneum in vivo.
  Kalia YN, Pirot F, Potts RO, Guy RH.
  J Pharm Sci. 1998 Dec;87(12):1508-11.

• The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail.
  Quintanar-Guerrero D, Ganem-Quintanar A, Tapia-Olguín P, Kalia YN, Buri P.
  Drug Dev Ind Pharm. 1998 Jul;24(7):685-90.

• Development of skin barrier function in premature infants.
  Kalia YN, Nonato LB, Lund CH, Guy RH.
  J Invest Dermatol. 1998 Aug;111(2):320-6.

• Transdermal drug delivery. Clinical aspects.
  Kalia YN, Merino V, Guy RH.
  Dermatol Clin. 1998 Apr;16(2):289-99. Review.

• Stratum corneum thickness and apparent water diffusivity: facile and noninvasive quantitation in vivo.
  Pirot F, Berardesca E, Kalia YN, Singh M, Maibach HI, Guy RH.
  Pharm Res. 1998 Mar;15(3):492-4. No abstract available.

• The effect of current on skin barrier function in vivo: recovery kinetics post-iontophoresis.
  Turner NG, Kalia YN, Guy RH.
  Pharm Res. 1997 Sep;14(9):1252-7.

• Transdermal therapy and diagnosis by iontophoresis.
  Merino V, Kalia YN, Guy RH.
  Trends Biotechnol. 1997 Aug;15(8):288-90. Review.

• Characterization of the permeability barrier of human skin in vivo.
  Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH.
  Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1562-7.

• Transdermal delivery of peptides by iontophoresis.
  Hirvonen J, Kalia YN, Guy RH.
  Nat Biotechnol. 1996 Dec;14(13):1710-3.

• Homogeneous transport in a heterogeneous membrane: water diffusion across human stratum corneum in vivo.
  Kalia YN, Pirot F, Guy RH.
  Biophys J. 1996 Nov;71(5):2692-700.

• The effect of iontophoresis on skin barrier integrity: non-invasive evaluation by impedance spectroscopy and transepidermal water loss.
  Kalia YN, Nonato LB, Guy RH.
  Pharm Res. 1996 Jun;13(6):957-60. No abstract available.

• In vitro study of percutaneous absorption, cutaneous bioavailability and bioequivalence of zinc and copper from five topical formulations.
  Pirot F, Millet J, Kalia YN, Humbert P.
  Skin Pharmacol. 1996;9(4):259-69.

• The electrical characteristics of human skin in vivo.
  Kalia YN, Guy RH.
  Pharm Res. 1995 Nov;12(11):1605-13.

Earlier¶

• Protein-protein recognition mediated by a mini-protein domain: possible evolutionary significance.
  Brocklehurst SM, Kalia YN, Perham RN.
  Trends Biochem Sci. 1994 Sep;19(9):360-1. No abstract available.

• The high-resolution structure of the peripheral subunit-binding domain of dihydrolipoamide acetyltransferase from the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus.
  Kalia YN, Brocklehurst SM, Hipps DS, Appella E, Sakaguchi K, Perham RN.
  J Mol Biol. 1993 Mar 5;230(1):323-41.

Book Chapter¶

• Correlation between impedance spectroscopy and transepidermal water loss: non-invasive probes of human skin permeability in vivo.
  Y. N. Kalia, L. B. Nonato, R. H. Guy. In: K. R. Brain, V. J. James and K. A. Walters (eds.), Prediction of Percutaneous Penetration, Volume 4B, STS Publishing Ltd., Cardiff, pp.38-41, (1996).
• Characterization of molecular transport across human stratum corneum in vivo.
  A. Naik, Y. N. Kalia, F. Pirot, R. H. Guy. In: R. Bronaugh and H. I. Maibach (eds.), Percutaneous Absorption 3rd ed., Marcel Dekker, New York, pp. 149-175, (1999).
• The development of skin barrier function in the neonate.
  L. B. Nonato, Y. N. Kalia, A. Naik, C. H. Lund, R. H. Guy. In: R. Bronaugh and H. I. Maibach (eds.), Percutaneous Absorption 3rd ed., Marcel Dekker, New York, pp. 825-860, (1999).
• Characterization of molecular transport across human stratum corneum in vivo.
  A. Naik, Y. N. Kalia, F. Pirot, R. H. Guy. In: R. Bronaugh and H. I. Maibach (eds.), Percutaneous Absorption: Drugs-Cosmetics-Mechanisms-Methodology, Marcel Dekker, New York (2001).
• The development of skin barrier function in the neonate.
  L. B. Nonato, Y. N. Kalia, A. Naik, C. H. Lund, R. H. Guy. In: R. Bronaugh and H. I. Maibach (eds.), Percutaneous Absorption: Drugs-Cosmetics-Mechanisms-Methodology, Marcel Dekker, New York (2001).
• Iontophoresis: Clinical applications and future challenges
  N. Abla, A. Naik, R. H. Guy, Y. N. Kalia. In: E. Smith and H. I. Maibach (eds.), Percutaneous Penetration Enhancers – Volume 2, CRC Press, Boca Raton (2006), pp 177-219.
• Transdermic system with cosmetic efficiency.
  Y. N. Kalia, J.-L. Levy, F. Garcia Pérez. In: J.-L. Levy (ed.), The Secrets of Anti-aging, Arnette (2007), pp 129-149.
• Clinical applications of transdermal iontophoresis.
  D. R. Kalaria, S. Dubey, Y. N. Kalia. In: H. Benson and A. Watkinson (eds.), Topical and transdermal drug delivery, John Wiley & Sons, Inc. (2011), pp 67-83.
• Stratum corneum ablation techniques.
  S. Dubey, D. R. Kalaria, T. Gratieri, Y. N. Kalia. In: R. F. V. Lopez, T. Gratieri and G. M. Gelfuso (eds.), Physical methods to increase topical and transdermal drug delivery, Transworld Research Network (2012), pp 145-159.
• Iontophoretic delivery of glycomimetics - a new approach for the treatment of inflammatory skin diseases.
  T. Gratieri, B. Wagner, D. Kalaria, B. Ernst, Y. N. Kalia. In: R. Chilcott and K. Brain (eds.), Advances in dermatological sciences, RSC, (2013), pp. 178-188.
• Topical iontophoresis for targeted local drug delivery to the eye and skin.
  T. Gratieri, Y. N. Kalia. In: A.V. Domb (ed.), Advances in delivery science and technology – Focal controlled drug delivery, Springer, (2014), pp 263-284.
• Iontophoresis.
  T Gratieri, Y. N. Kalia. In: N. Dragicevic-Curic and H. I. Maibach (eds.), Percutaneous Penetration Enhancers – Springer, in press.
• Iontophoretic transport mechanisms and factors affecting electrically-assisted delivery.
  T Gratieri, Y. N. Kalia. In: N. Dragicevic-Curic and H. I. Maibach (eds.), Percutaneous Penetration Enhancers – Springer, in press.
• Polymeric micelles in dermal and transdermal delivery.
  M. Lapteva, M. Möller, Y. N. Kalia. In: N. Dragicevic-Curic and H. I. Maibach (eds.), Percutaneous Penetration Enhancers – Springer, in press.
• Liquid crystals in dermal and transdermal delivery.
  M. Lapteva, Y. N. Kalia. In: K. Sugibayashi (eds.), Skin Permeation and Disposition of Therapeutic and Cosmeceutical Compounds – Springer (Japan), in press.
• Encapsulation technologies: Polymeric micelles in dermal and transdermal delivery.
  M. Lapteva, Y. N. Kalia. In: K. Sugibayashi (eds.), Skin Permeation and Disposition of Therapeutic and Cosmeceutical Compounds – Springer (Japan), in press.
• Iontophoresis and electroporation.
  M. Singhal, Y. N. Kalia. In: K. Sugibayashi (eds.), Skin Permeation and Disposition of Therapeutic and Cosmeceutical Compounds – Springer (Japan), in press.